Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-101, which is being developed in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients in first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.
CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with...
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.
FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a...
Florham Park, N.J. & San Diego, C.A., September 20, 2021: Celularity Inc. (“Celularity”) (Nasdaq: CELU),...
Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25...
Secured funding of approximately $138 million through merger and private placement investment in public equity...
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus...
Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital...
The Brain Mapping Foundation and the Society for Brain Mapping and Therapeutics to celebrate this...
Arthrex to receive exclusive rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics...
No dose limiting toxicity to date with outpatient administration of three doses (Days 0, 7...
Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across...
Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data...
NEW YORK, April 16, 2021 /PRNewswire/ — On April 14, 2021, GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information...
On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA)...
FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology...
Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease FLORHAM...